Users Online: 670 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Login 


RSACP wishes to inform that it shall be discontinuing the dispatch of print copy of JOACP to it's Life members. The print copy of JOACP will be posted only to those life members who send us a written confirmation for continuation of print copy.
Kindly email your affirmation for print copies to dranjugrewal@gmail.com preferably by 30th June 2019.

 

 
Table of Contents
LETTER TO EDITOR
Year : 2013  |  Volume : 29  |  Issue : 4  |  Page : 570-571

Ivabradine in sepsis


Department of Anesthesiology, Care Hospital, Banjara Hills, Axon Anesthesia Associates, Hyderabad, Andhra Pradesh, India

Date of Web Publication1-Oct-2013

Correspondence Address:
Abhijit S Nair
Department of Anesthesiology, Care Hospital, Banjara Hills, Road No. 1, Hyderabad 500 034
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0970-9185.119154

Rights and Permissions

How to cite this article:
Nair AS, Gopal T. Ivabradine in sepsis . J Anaesthesiol Clin Pharmacol 2013;29:570-1

How to cite this URL:
Nair AS, Gopal T. Ivabradine in sepsis . J Anaesthesiol Clin Pharmacol [serial online] 2013 [cited 2019 Jun 27];29:570-1. Available from: http://www.joacp.org/text.asp?2013/29/4/570/119154

Sir,

Persistent tachycardia in sepsis or multi-organ dysfunction syndrome (MODS) is an ominous sign. [1] This usually comes under control with judicious use of antibiotics, fluid resuscitation, sedation. Uncontrolled tachycardia in systemic inflammatory response syndrome and sepsis deprives the heart muscle of oxygen. As it progresses, insufficient heart muscle nutrition eventually leads to myocardial dysfunction. It can also present as heart failure, systolic heart failure or diastolic heart failure. In acute coronary syndromes, beta blockers are used to control heart rate. However in MODS, it cannot be used due to hemodynamic instability and worsened myocardial function.

Sinoatrial (SA) myocytes are the pacemaker cells in the heart. [2],[3] Pacemaker activity involves several ionic currents that influences spontaneous depolarization of SA node including If current. The word "f " means funny" because this current has unusual properties as compared with other currents known at the time of its discovery. If current is carried out by sodium and potassium ions across the sarcolemma. It is one of the most important ionic current for regulating pacemaker activity in SA node.

Ivabradine is a If current inhibitor in SA node. [2],[3] Currently, it is the only agent shown to clinically lower heart rate with no negative inotropism or effects on conduction and contractility. [2],[3] Ivabradine selectively inhibits the pacemaker If current in a dose dependent manner at concentrations that do not affect other cardiac ion currents. Blocking this channel reduces cardiac pacemaker activity, slowing the heart rate and allowing more time for blood flow to the myocardium. The dosing is started at 5 mg twice daily, and if tolerated can be safely continued to 7.5 mg twice daily. Food delays the absorption of ivabradine. As metabolism involves cytochrome P4503A4 (CYP3A4), concurrent use of inhibitors of CYP3A4 (macrolide antibiotics, azole antifungals) is contraindicated. Metabolites are excreted in urine and feces. Main t ½ is 2 h (70-75% of area under the curve) in plasma and has an effective t ½ of 11 h. Total clearance is 400 ml/min and renal clearance is 70 ml/min. The various adverse effects of ivabradine includes luminous phenomenon (due to blockade of Ih channel in the retina, which resembles If cardiac channels), atrioventricular block, ventricular extrasystole and bradycardia. [3]



 
  References Top

1.Muller-Werdan U, Buerke M, Ebelt H, Heinroth KM, Herklotz A, Loppnow H, et al. Septic cardiomyopathy-A not yet discovered cardiomyopathy? Exp Clin Cardiol 2006;11:226-36.  Back to cited text no. 1
    
2.Shettock MJ, Camm AJ. Pure heart rate reduction: The if channel from discovery to therapeutic targets. Br J Cardiol 2006;13:27-35.  Back to cited text no. 2
    
3.Sulfi S, Timmis AD. Ivabradine: The first selective sinus node I (f) channel inhibitor in the treatment of stable angina. Int J Clin Pract 2006;60:222-8.  Back to cited text no. 3
    



This article has been cited by
1 Ivabradine: Evidence and current role in cardiovascular diseases and other emerging indications
I. Sathyamurthy,Sanket Newale
Indian Heart Journal. 2018;
[Pubmed] | [DOI]
2 Is There a Role for Ivabradine Beyond its Conventional Use?
Ivano Bonadei,Enrico Vizzardi,Edoardo Sciatti,Valentina Carubelli,Carlo Mario Lombardi,Antonio DęAloia,Marco Metra
Cardiovascular Therapeutics. 2014; 32(4): 189
[Pubmed] | [DOI]



 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
   References

 Article Access Statistics
    Viewed2065    
    Printed37    
    Emailed0    
    PDF Downloaded465    
    Comments [Add]    
    Cited by others 2    

Recommend this journal